PRC200-SS

PRC200-SS
Identifiers
	IUPAC name (1S,2S)-3-(Methylamino)-2-naphthalen-2-yl-1-phenylpropan-1-ol;
CAS Number	492434-58-9 ;
PubChem CID	20631904;
ChemSpider	19318181 ;
UNII	V9MLT2S334;
CompTox Dashboard (EPA)	DTXSID101028763 ;
ECHA InfoCard	100.207.294
Chemical and physical data
Formula	C20H21NO
Molar mass	291.394 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES O[C@H](c1ccccc1)[C@H](CNC)c2cc3ccccc3cc2;
	InChI InChI=1S/C20H21NO/c1-21-14-19(20(22)16-8-3-2-4-9-16)18-12-11-15-7-5-6-10-17(15)13-18/h2-13,19-22H,14H2,1H3/t19-,20-/m1/s1 ; Key:RSZGIFQDUIROGN-WOJBJXKFSA-N ;
	(what is this?) (verify)

PRC200-SS is an experimental drug of the triple reuptake inhibitor class that was investigated by the Mayo Clinic.^[1]^[2] Preclinical toxicology studies of PRC200-SS in cynomolgus monkeys showed dose proportional kidney toxicity,^[3] precluding any further drug development.

References

↑ Liang Y, Shaw AM, Boules M, Briody S, Robinson J, Oliveros A, et al. (November 2008). "Antidepressant-like pharmacological profile of a novel triple reuptake inhibitor, (1S,2S)-3-(methylamino)-2-(naphthalen-2-yl)-1-phenylpropan-1-ol (PRC200-SS)". The Journal of Pharmacology and Experimental Therapeutics. 327 (2): 573–83. doi:10.1124/jpet.108.143610. PMID 18689611. S2CID 12635418.
↑ "Triple Reuptake Inhibitors for the Treatment of Depression". Mayo Clinic Ventures.
↑ Guha M, Heier A, Price S, Bielenstein M, Caccese RG, Heathcote DI, et al. (April 2011). "Assessment of biomarkers of drug-induced kidney injury in cynomolgus monkeys treated with a triple reuptake inhibitor". Toxicological Sciences. 120 (2): 269–83. doi:10.1093/toxsci/kfr013. PMID 21258088.